| For: | Singh A, Sohal A, Batta A. GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World J Gastroenterol 2024; 30(48): 5205-5211 [PMID: 39735270 DOI: 10.3748/wjg.v30.i48.5205] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v30/i48/5205.htm |
| Number | Citing Articles |
| 1 |
A. Pariente. Hepatopatías esteatósicas dismetabólicas. EMC - Tratado de Medicina 2025; 29(4) doi: 10.1016/S1636-5410(25)51059-0
|
| 2 |
Hao-Yao Pan, Wei-Wei Chen, Jia-Xin Liang, Yi-Yang Sheng, Wen-Jing Zhang, Xue-Wen Zhu, Shuai-Yan Wang, Guan-Hu Yang, Yun Liu, Tian-Cheng Xu. Pancreatic-liver crosstalk, novel molecular mediators, and 2025 therapeutic breakthroughs. World Journal of Methodology 2026; 16(3): 118728 doi: 10.5662/wjm.v16.i3.118728
|
| 3 |
Zhi-Hao Xi, Wen-Jie Sun, Ming-Hui Li, Qi-Qi Dong, Xue Dong, Zheng-Lin Qiao, Hui Tao, Jing-Jing Yang, Chao Lu. Extracellular matrix stiffness in chronic liver disease: From mechanisms to treatments. Biochemical Pharmacology 2026; 252 doi: 10.1016/j.bcp.2026.118194
|
| 4 |
Ralf Weiskirchen. Resmetirom and semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): a comparative perspective. Exploration of Drug Science 2025; 3 doi: 10.37349/eds.2025.1008132
|
| 5 |
Yu-Nan Huang, Pei-Yun Li, Kai-Wen Liu, Pin-Hung Li, Shao-Chia Chen, Jo-Ching Chen, Gideon Meyerowitz-Katz, Jing-Yang Huang, Pen-Hua Su. Associations of mortality and sepsis after GLP-1 receptor agonist initiation versus SGLT2 inhibitor or metformin initiation in people with HIV, overweight or obesity, and type 2 diabetes: A target trial emulation. Therapeutic Advances in Endocrinology and Metabolism 2026; 19 doi: 10.1177/20420188261490985
|
| 6 |
Md Entaz Bahar, Deok Ryong Kim. Cell type–specific paradox of autophagy and senescence in MASH: implications for precision hepatology. Frontiers in Cell and Developmental Biology 2026; 14 doi: 10.3389/fcell.2026.1837383
|
| 7 |
Xinyi Zhang, Nanqin Peng, Xiaoyue Zhang, Zicheng Zhu, Yan Miao, Yuting Wu, Jitao Ling, Chen Li, Wenli Gu, Jing Zhang, Abudukeremu Ayiguli, Ziheng Zheng, Peng Yu, Xiao Liu. Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation, cardiac arrest, and ventricular fibrillation: Casual evidence from a drug target Mendelian randomization. Diabetology & Metabolic Syndrome 2025; 17(1) doi: 10.1186/s13098-025-01712-w
|
| 8 |
Surtika Tamilwanan, Zoriah Aziz, Lim Yan Rong, Ahmad Naoras Bitar, Raghdaa Hamdan Al Zarzour, Salah A. Alshehade. Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials. BMC Gastroenterology 2025; 25(1) doi: 10.1186/s12876-025-04358-0
|
| 9 |
Roberta Chianetta, Lydia Giannitrapani, Alessio Giuseppe Lipari, Assunta Brunone, Claudia Cannizzo, Roberto Citarrella, Maurizio Soresi, Antonio Liguori, Nadia Panera, Filomena Morisco, Luca Miele, Anna Licata. Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease. Biomolecules 2026; 16(6) doi: 10.3390/biom16060797
|
| 10 |
Jiayi Chen, Shiyun Wu, Panpan Zhai, Xueting Ou, Liyang Zhou, Xingfei Pan. Global burden of hepatitis C virus infection related to high body mass index and future forecast: an analysis based on the global burden of disease study 2021. Frontiers in Public Health 2025; 13 doi: 10.3389/fpubh.2025.1685807
|
| 11 |
Angeliki Margoni, Kostas A. Papavassiliou, Athanasios G. Papavassiliou. Deliberating the striking effect of dual GLP-1R and GIPR agonists on “Diabesity” in light of precision medicine and pharmacogenomics. Metabolism Open 2025; 28 doi: 10.1016/j.metop.2025.100409
|
| 12 |
Iago Justo, María Calatayud, Javier Salamanca, María Camara, Alvaro García-Sesma, Carmelo Loinaz. Can we decrease the risk of complex liver surgery with the new GLP1 and GIP analogues?. Cirugía Española 2026; 104(4) doi: 10.1016/j.ciresp.2025.800264
|
| 13 |
Chuhan Zeng, Qiuxia Lu, Qi Zhao, Jian Li. Mechanisms and reversal strategies of liver fibrosis: from regulation of cell fate to clinical translation. Journal of Translational Medicine 2026; 24(1) doi: 10.1186/s12967-026-08312-w
|
| 14 |
Adam Vašura, Evžen Machytka, Marek Bužga, Jitka Macháčková, Jan Král. The significance of metabolism-associated steatotic liver disease and its treatment. Vnitřní lékařství 2025; 71(1) doi: 10.36290/vnl.2025.005
|
| 15 |
Shi-ping Sun, Yan Fang, Li Liu, Yi Li, Han Min. GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1800909
|
| 16 |
Cristina Scavone, Michele Cerasuolo, Mario Gaio, Nicoletta Lettera, Francesca Futura Bernardi, Annalisa Capuano, Barbara Rinaldi. Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1882225
|
| 17 |
Amirmohammad Abolhassani, Mohammed H. Moghadasian, Niloofar Sedaghatnezhad, Sadegh Jafarnejad. Anti-Dyslipidemic, Anti-Hypertensive, and Glycemic Control Effects of Akkermansia Muciniphila: Lesser-Known Benefits in Metabolic Syndrome – A Narrative Review. Heart and Mind 2025; 9(5) doi: 10.4103/hm.HM-D-24-00161
|
| 18 |
Natalie Eppler, Elizabeth Jones, Forkan Ahamed, Yuxia Zhang. Multifaceted Human Antigen R (HuR): A Key Player in Liver Metabolism and MASLD. Livers 2025; 5(3) doi: 10.3390/livers5030033
|
| 19 |
Meenakshi R. YATHINDRA, Ayush BHATTACHARJEE, Nikhil PUNDIR, Pooja PATEL, Nidhi E. JACOB, Preeti E. JOSSY, Rajmohan SEETHARAMAN. A review of survodutide: a new dual acting agonist. Minerva Endocrinology 2026; 51(3) doi: 10.23736/S2724-6507.26.04406-4
|
| 20 |
Xiaohan Bu, Mengzhe Dai, Zhen Fang, Jun Zou, Shengyong Yang. Discovery of Fisetin as a potent and cell-active ACVR2A inhibitor. Bioorganic & Medicinal Chemistry Letters 2027; 142 doi: 10.1016/j.bmcl.2026.130786
|
| 21 |
Stjepan Skudar. Quadruple Non-Insulin Therapy for Advanced Type 2 Diabetes Mellitus With Cognitive Impairment: A Case Report. Cureus 2026; doi: 10.7759/cureus.108113
|
| 22 |
Giacinta Ciancimino, Fabiana Pecorella, Silvia Maria Viscardi, Claudia La Mantia, Antonino Caserta, Grazia Pennisi, Salvatore Petta. Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual and triple agonists - mechanisms, clinical evidence, and therapeutic perspectives. Hepatoma Research 2026; doi: 10.20517/2394-5079.2026.19
|
| 23 |
Ken Fujioka. Effect of GLP‐1 receptor agonist on nutrient intake: A narrative review. Nutrition in Clinical Practice 2026; 41(5) doi: 10.1002/ncp.70172
|
| 24 |
Lifen Xue, Xin Wang, Jingxin Mao. Research progress on the mechanistic pathways and biomarkers of therapeutic drugs for metabolic-associated steatotic liver disease. Frontiers in Cell and Developmental Biology 2026; 14 doi: 10.3389/fcell.2026.1808135
|
| 25 |
Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano. The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management. Exploration of Medicine 2025; 6 doi: 10.37349/emed.2025.1001365
|
| 26 |
Pranav Patel. Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease. Journal of Clinical Medicine 2025; 14(17) doi: 10.3390/jcm14176060
|
| 27 |
Shi-ping Sun, Chen-xi Wang, Ming-kai Yuan, Han Min. GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trials. Hepatology International 2026; doi: 10.1007/s12072-026-11132-1
|
| 28 |
Yilmaz Gunes. A brief approach to hypertension in type 2 diabetes mellitus. Exploration of Endocrine and Metabolic Diseases 2025; doi: 10.37349/eemd.2025.101422
|
| 29 |
Junyu Wang, Jingting Lei, Martin C. Harmsen, Han Moshage. From cooperation to collapse: systemic failure in liver disease through a sociological lens. Exploration of Digestive Diseases 2025; 4 doi: 10.37349/edd.2025.100580
|
| 30 |
Ileana Pantea, Angela Repanovici, Hamza Islam. Tirzepatide in Metabolically Dysfunctional‐Associated Steatohepatitis (MASH): A Bibliometric and Evidence‐Based Review. Journal of Diabetes Research 2026; 2026(1) doi: 10.1155/jdr/1853763
|
| 31 |
Karolina Kornatowska, Szymon Kopciał, Mateusz Wiekiera, Adrianna Wiekiera, Paweł Budzik, Mateusz Tyniec, Kamal Morshed. The Evolution of MASLD Management: From Revised Nomenclature to Disease-Modifying Therapies. Gastroenterology Insights 2026; 17(2) doi: 10.3390/gastroent17020033
|
| 32 |
L. B. Lazebnik, E. V. Vinnitskaya. The thyroid hormone receptor beta (THR-β) agonist resmetir for the treatment of liver fi brosis and steatohepatitis. Experimental and Clinical Gastroenterology 2026; (12) doi: 10.31146/1682-8658-ecg-244-12-113-118
|
| 33 |
A. Pariente. Hépatopathies stéatosiques dysmétaboliques. EMC - Traité de médecine AKOS 2025; 28(3) doi: 10.1016/S1634-6939(25)49520-9
|
| 34 |
Joya Ghaleb, Katy Kaleen Khouzami, Nicolas Nassif, Philippe Attieh, Mohammad Feras Al Ajlani, Jana Bou Sleiman, Ali Khalouf, Frederic Harb, Sami Azar, Amjad Kanaan, Hilda E. Ghadieh, Suraiya Saleem. Unveiling Tirzepatide’s Therapeutic Spectrum: A Dual GIP/GLP‐1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health. International Journal of Endocrinology 2025; 2025(1) doi: 10.1155/ije/2876156
|
| 35 |
Mustafa Karabicici, Ekihiro Seki. Metabolic Dysfunction–Associated Steatotic Liver Disease Reprograms the Hepatic Metastatic Niche. Seminars in Liver Disease 2026; 46(02) doi: 10.1055/a-2921-0092
|
| 36 |
Arthur Anatolievich Lee, Victoria Alexandrovna Khotina, Dmitry Alexandrovich Kashirskikh, Olga Evgenevna Voronko, Vagif Ali oglu Gasanov, Andrey Valentinovich Vasiliev. Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact. Medical Sciences 2025; 13(4) doi: 10.3390/medsci13040269
|
| 37 |
Fang Yao, Gaochao Wang, Fan Ning, Yanbo Shi. Targeting Ferroptosis: New Insights and Therapeutic Advances in MAFLD Complicating T2DM. Frontiers in Bioscience-Landmark 2025; 30(10) doi: 10.31083/FBL39735
|
| 38 |
Xing Wan, Jingyuan Ma, He Bai, Xuyang Hu, Yanna Ma, Mingjian Zhao, Jifeng Liu, Zhijun Duan. Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs. Biomolecules 2025; 15(1) doi: 10.3390/biom15010140
|
| 39 |
Vidhu Vadini, Daisy Duan, Kendall F Moseley. Impact of glucagon-like peptide-1 receptor agonists on bone metabolism. The Journal of Clinical Endocrinology & Metabolism 2026; doi: 10.1210/clinem/dgag323
|
| 40 |
Shujun Li, Nanqu Huang, Mei Wang, Wendi Huang, Yong Luo, Juan Huang. GLP-1R in diabetes mellitus: from basic discovery to therapeutics development. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1610512
|
| 41 |
Piotr Olejnik, Kaja Kasarełło, Renata Podkowińska-Polak, Aleksandra Golenia. Psoriasis: an emerging risk factor for ischemic stroke?. Frontiers in Neurology 2025; 16 doi: 10.3389/fneur.2025.1599978
|
| 42 |
Anna Giannakogeorgou, Michael Roden, Kalliopi Pafili. Diabetes mellitus as a multisystem disease: understanding subtypes, complications, and the link with steatotic liver diseases in humans. Hormones 2026; 25(1) doi: 10.1007/s42000-025-00701-y
|
| 43 |
Senping Xu, Zhaoshan Zhang, Zhongquan Zhou, Jiawei Guo. Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation. Biology 2026; 15(2) doi: 10.3390/biology15020148
|
| 44 |
Iago Justo, María Calatayud, Javier Salamanca, María Camara, Alvaro García-Sesma, Carmelo Loinaz. Can we decrease the risk of complex liver surgery with the new GLP1 and GIP analogues?. Cirugía Española (English Edition) 2026; 104(4) doi: 10.1016/j.cireng.2025.800264
|
| 45 |
Krishna Bonga, Milan Padhan. Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control. Rambam Maimonides Medical Journal 2026; 17(1) doi: 10.5041/RMMJ.10565
|
| 46 |
Sophie Betty Brock, Nina Lerberg Hansen, Elvar Már Sturlaugsson Jóhönnuson, Sasha Alexandra Sampson Kjeldsen, Nicolai J. Wewer Albrechtsen. Dose–Response Effect of Glucagon on Glucose, Beta‐Cell Secretion and Metabolism in Healthy Individuals. Diabetes, Obesity and Metabolism 2026; 28(8) doi: 10.1111/dom.70896
|
| 47 |
Mei-jun Wang, Yu-nuo Jiang, Pei-pei Li, Yuan-Jie Wu. Impact of Glucagon-Like Peptide-1 Receptor Agonists on Liver-Related Outcomes, Laboratory and Physiologic Parameters in Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis. Diabetes, Metabolic Syndrome and Obesity 2026; doi: 10.2147/DMSO.S565093
|
| 48 |
Zubaier Ahmed, Nashrah Mustafa, Tamanna Sarkar, Hasina Yasmin. Beyond Weight Loss: Tirzepatide as a Metabolic Disease‐Modifying Strategy for Metabolic Dysfunction‐Associated Steatohepatitis: A Narrative Review. Health Science Reports 2026; 9(8) doi: 10.1002/hsr2.73044
|
| 49 |
Tariq Alrasheed, Mohamed E. A. Mostafa, Mohammed A Madkhali, Hesham A Khairy. Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis. Frontiers in Endocrinology 2026; 16 doi: 10.3389/fendo.2025.1734549
|
| 50 |
Stefano Fiorucci, Ginevra Urbani. Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives. Expert Opinion on Investigational Drugs 2025; 34(9) doi: 10.1080/13543784.2025.2546812
|